Integrative targeted therapy for renal cancer
Facts about kidney (also called renal) cancer: Cancer of the kidneys is the sixth most common cancer for men and the eighth most common cancer for women. Approximately 85% of…
A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report
Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first…
Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report
A 25‐year‐old nulliparous woman was diagnosed with a primary malignant melanoma of the uterine cervix stage IVA. She has undergone surgery three times. The oncolytic virus Rigvir® was prescribed between the…
Rigvir holding concludes a deal with Chinese biotech company Sinorda Biomedicine on development and commercialisation of Oncolytic virotherapy cancer medicine in Chinese market
Rigvir holding concludes a deal with Chinese biotech company Sinorda Biomedicine on development and commercialisation of ECHO-7 oncolytic virotherapy cancer medicine in Chinese market and agrees on sales of minority…
Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines
Uveal melanoma is a rare intraocular malignancy. Half of the patients diagnosed will develop metastases within 10 to 30 years, most commonly in the liver. Although there has been a…
Oncolytic Virotherapy Market News
The oncolytic virus treatment market becomes more and more active for the pharma industry, and we can expect a lot of oncolytic virus medicines in the nearest future. An article…
ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report
A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy the state of her eye worsened until tumor growth was…
Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir
Laryngeal cancer can cause irreversible damage to the vocal cords, resulting in loss of voice. This report describes a stage III glottic cancer patient treated with Rigvir therapy, showing good…
